Skip to main content
Top

Clinical & Experimental Metastasis

Issue 1/2003

Genetics of Metastasis – Part 1

Content (12 Articles)

Introduction

Danny R. Welch, Ann F. Chambers

Inhibition of signal transduction by the nm23 metastasis suppressor: Possible mechanisms

Massimiliano Salerno, Taoufik Ouatas, Diane Palmieri, Patricia S. Steeg

KISS1 metastasis suppression and emergent pathways

John F. Harms, Danny R. Welch, Mary E. Miele

Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation

Garth L. Nicolson, Akihiro Nawa, Yasushi Toh, Shigeki Taniguchi, Katsuhiko Nishimori, Amr Moustafa

MKK4 and metastasis suppression: A marriage of signal transduction and metastasis research

Victoria L. Robinson, Jonathan A. Hickson, Donald J. Vander Griend, Zita Dubauskas, Carrie W. Rinker-Schaeffer

Breast cancer metastasis suppressor 1: Update

William J. Meehan, Danny R. Welch

Collapsin response mediator protein-1: A novel invasion-suppressor gene

Jin-Yuan Shih, Yuan-Chii G. Lee, Shuenn-Chen Yang, Tse-Ming Hong, Chi-Ying F. Huang, Pan-Chyr Yang

Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter

David T. Denhardt, Devra Mistretta, Ann F. Chambers, Shuba Krishna, Joseph F. Porter, Srilatha Raghuram, Susan R. Rittling

Osteopontin and colon cancer progression

Timothy J. Yeatman, Ann F. Chambers

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine